RT Journal Article
SR Electronic
T1 Association of frailty, age, and biological sex with SARS-CoV-2 mRNA vaccine-induced immunity in older adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.11.22272269
DO 10.1101/2022.03.11.22272269
A1 Shapiro, Janna R.
A1 Park, Han-Sol
A1 Aytenfisu, Tihitina Y.
A1 Caputo, Christopher
A1 Lee, John
A1 Johnston, Trevor S.
A1 Li, Huifen
A1 Hauk, Pricila
A1 Jacobsen, Henning
A1 Li, Yukang
A1 Abrams, Engle
A1 Kocot, Andrew J.
A1 Yang, Tianrui
A1 Huang, Yushu
A1 Cramer, Steven M.
A1 Betenbaugh, Michael J.
A1 Debes, Amanda K.
A1 Morgan, Rosemary
A1 Milstone, Aaron M.
A1 Karaba, Andrew H.
A1 Leng, Sean X.
A1 Klein, Sabra L.
YR 2022
UL http://medrxiv.org/content/early/2022/03/13/2022.03.11.22272269.abstract
AB Background Male sex and old age are risk factors for severe COVID-19, but the intersection of sex and aging on antibody responses to SARS-CoV-2 vaccines has not been characterized.Methods Plasma samples were collected from older adults (75-98 years) before and after three doses of SARS-CoV-2 mRNA vaccination, and from younger adults (18-74 years) post-dose two, for comparison. Antibody binding to SARS-CoV-2 antigens (spike protein [S], S-receptor binding domain [S-RBD], and nucleocapsid [N]) and functional activity against S were measured against the vaccine virus and variants of concern (VOC).Results Vaccination induced greater antibody titers in older females than males, with both age and frailty associated with reduced antibody responses to vaccine antigens in males, but not females. ACE2 binding inhibition declined more than anti-S or anti-S-RBD IgG in the six months following the second dose (28-fold vs. 12- and 11-fold decreases in titer). The third dose restored functional antibody responses and eliminated disparities caused by sex, age, and frailty in older adults. Responses to the VOC were significantly reduced relative to the vaccine virus, with older males having lower titers to the VOC than females. Older adults had lower responses to the vaccine and VOC viruses than younger adults, with disparities being greater in males than females.Conclusion Older and frail males may be more vulnerable to breakthrough infections due to low antibody responses before receipt of a third vaccine dose. Promoting third dose coverage in older adults, especially males, is crucial to protecting this vulnerable population.Brief summary SARS-CoV-2 mRNA vaccination induces greater antibody response in older females than males, and age and frailty reduce responses in males only. These effects are eliminated by a third vaccine dose, highlighting the need for third dose coverage, especially in older males.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the NIH/NIA Specialized Center of Research Excellence U54 AG062333 awarded to S.L.K. and the NIH/NCI COVID-19 Serology Center of Excellence (U54 CA260492 awarded to S.L.K. This work was also supported by funding from the Milstein Medical Asian American Partnership (MMAAP) Foundation of USA as well as Howard and Abby Milstein Foundation awarded to S.X.L, and by the generosity of the collective community of donors to the Johns Hopkins University School of Medicine and the Johns Hopkins Health System for Covid-19 research. J.R.S was supported by a training award from the Fonds de recherche du Quebec Sante (File 287609).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of the Johns Hopkins School of Medicine gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors